Sponsored

A patient treated with a single dose of AdAlta’s experimental CAR T cell therapy EW 001 has remained free of cancer recurrence for two years, marking a significant milestone in the company’s ongoing mesothelioma study in China.

Clarity Pharmaceuticals has reported two additional complete responses among participants receiving its investigational radiopharmaceutical 67Cu-SAR-bisPSMA in the SECuRE trial, bringing the total number of complete responses or cases of undetectable disease across the company’s program to seven.

QIMR Berghofer and James Cook University have strengthened their strategic partnership to establish one of Australia’s leading collaborations in tropical health research, with a focus on accelerating the development of vaccines, diagnostics and therapeutics while preparing the next generation of health researchers.

Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner, Acadia Pharmaceuticals, reporting net sales of US$125 million in the second quarter of 2026.

Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients.

Entropy Neurodynamics has received approval from the Human Research Ethics Committee to begin a Phase 1b/2a basket study of TRP-8803, its proprietary intravenous psilocin formulation.

Amplia Therapeutics has entered into a clinical trial collaboration and supply agreement with Eli Lilly to evaluate whether its investigational FAK inhibitor narmafotinib can improve treatment outcomes when combined with Lilly’s next-generation KRAS G12C inhibitor olomorasib.

Noxopharm has reported preclinical results showing that its technology can help the immune system recognise cellular RNA that would normally fail to trigger an anti-cancer response.

Neurizon Therapeutics has entered into a strategic research and development financing facility with the Dare Capital Loan Fund, providing up to $17.5 million in additional capital to support its work on treatments for neurodegenerative diseases.

Neurizon Therapeutics says it expects a registrational readout for NUZ-001 in 2027 as the company moves its oral, repurposed candidate through the HEALEY ALS Platform Trial toward a potential pivotal result.

CSL has announced it will begin clinical trials to evaluate the safety and efficacy of immunoglobulin produced with its next-generation Horizon 2 manufacturing process.

AusBiotech has launched a new membership category in its 40th year, AusBiotech Connect, designed specifically for companies in their first two years of operation.